Показано 0 из 0
Дата |
---|
03.05.2024 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
1.11
|
1.16
|
1.12
|
1.11
|
1.13
|
1.13
|
|
|
4 615.14
|
44.00
|
1.10
|
1.14
|
1.16
|
1.11
|
1.16
|
1.115
|
|
|
5 532.88
|
46.00
|
1.10
|
1.17
|
1.15
|
1.12
|
1.15
|
1.14
|
|
|
20 562.64
|
62.00
|
1.06
|
1.10
|
1.24
|
1.09
|
1.24
|
1.115
|
|
|
72 758.27
|
112.00
|
1.23
|
1.25
|
1.03
|
1.01
|
1.28
|
1.21
|
|
|
170 341.43
|
272.00
|
0.96
|
1.10
|
0.96
|
0.96
|
1.02
|
1.02
|
|
|
7 933.78
|
29.00
|
0.97
|
1.06
|
1.05
|
0.94
|
1.05
|
0.97
|
|
|
24 511.95
|
43.00
|
0.99
|
1.20
|
1.07
|
1.0383
|
1.08
|
1.0383
|
|
|
29 607.08
|
138.00
|
1.07
|
1.10
|
1.17
|
1.07
|
1.17
|
1.07
|
|
|
28 539.69
|
73.00
|
1.10
|
1.20
|
1.09
|
1.07
|
1.19
|
1.15
|
|
|
21 378.30
|
115.00
|
Unicycive Therapeutics Inc is a biotechnology company dedicated towards developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.